855 related articles for article (PubMed ID: 22068922)
21. Effects of AZD3480 on cognition in patients with mild-to-moderate Alzheimer's disease: a phase IIb dose-finding study.
Frölich L; Ashwood T; Nilsson J; Eckerwall G;
J Alzheimers Dis; 2011; 24(2):363-74. PubMed ID: 21258153
[TBL] [Abstract][Full Text] [Related]
22. Rivastigmine versus placebo in hyperhomocysteinemic Parkinson's disease dementia patients.
Barone P; Burn DJ; van Laar T; Hsu C; Poewe W; Lane RM
Mov Disord; 2008 Aug; 23(11):1532-40. PubMed ID: 18581467
[TBL] [Abstract][Full Text] [Related]
23. Effects of switching from an AChE inhibitor to a dual AChE-BuChE inhibitor in patients with Alzheimer's disease.
Bartorelli L; Giraldi C; Saccardo M; Cammarata S; Bottini G; Fasanaro AM; Trequattrini A;
Curr Med Res Opin; 2005 Nov; 21(11):1809-18. PubMed ID: 16307702
[TBL] [Abstract][Full Text] [Related]
24. A 24-week, randomized, controlled trial of rivastigmine patch 13.3 mg/24 h versus 4.6 mg/24 h in severe Alzheimer's dementia.
Farlow MR; Grossberg GT; Sadowsky CH; Meng X; Somogyi M
CNS Neurosci Ther; 2013 Oct; 19(10):745-52. PubMed ID: 23924050
[TBL] [Abstract][Full Text] [Related]
25. Rivastigmine Patch in Chinese Patients with Probable Alzheimer's disease: A 24-week, Randomized, Double-Blind Parallel-Group Study Comparing Rivastigmine Patch (9.5 mg/24 h) with Capsule (6 mg Twice Daily).
Zhang ZX; Hong Z; Wang YP; He L; Wang N; Zhao ZX; Zhao G; Shang L; Weisskopf M; Callegari F; Strohmaier C
CNS Neurosci Ther; 2016 Jun; 22(6):488-96. PubMed ID: 27012596
[TBL] [Abstract][Full Text] [Related]
26. The Atorvastatin/Donepezil in Alzheimer's Disease Study (LEADe): design and baseline characteristics.
Jones RW; Kivipelto M; Feldman H; Sparks L; Doody R; Waters DD; Hey-Hadavi J; Breazna A; Schindler RJ; Ramos H;
Alzheimers Dement; 2008 Mar; 4(2):145-53. PubMed ID: 18631958
[TBL] [Abstract][Full Text] [Related]
27. Medial temporal lobe atrophy and APOE genotype do not predict cognitive improvement upon treatment with rivastigmine in Alzheimer's disease patients.
Visser PJ; Scheltens P; Pelgrim E; Verhey FR;
Dement Geriatr Cogn Disord; 2005; 19(2-3):126-33. PubMed ID: 15627759
[TBL] [Abstract][Full Text] [Related]
28. Rivastigmine patch for treatment of Alzheimer's disease in clinical practice in Thailand.
Kulkantrakorn K; Tanyakitpisal P; Towanabut S; Dejthevaporn C; Rangseekajee P; Pongpakdee S; Laptikultham S; Rodprasert K; Setthawatcharawanich S; Thinkhamrop B
Psychogeriatrics; 2013 Mar; 13(1):1-8. PubMed ID: 23551405
[TBL] [Abstract][Full Text] [Related]
29. Analysis of the effect of memantine in reducing the worsening of clinical symptoms in patients with moderate to severe Alzheimer's disease.
Wilkinson D; Andersen HF
Dement Geriatr Cogn Disord; 2007; 24(2):138-45. PubMed ID: 17622761
[TBL] [Abstract][Full Text] [Related]
30. Effect of butyrylcholinesterase genotype on the response to rivastigmine or donepezil in younger patients with Alzheimer's disease.
Blesa R; Bullock R; He Y; Bergman H; Gambina G; Meyer J; Rapatz G; Nagel J; Lane R
Pharmacogenet Genomics; 2006 Nov; 16(11):771-4. PubMed ID: 17047484
[TBL] [Abstract][Full Text] [Related]
31. Rivastigmine for Alzheimer's disease.
Birks JS; Grimley Evans J
Cochrane Database Syst Rev; 2015 Apr; (4):CD001191. PubMed ID: 25858345
[TBL] [Abstract][Full Text] [Related]
32. Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period.
Bullock R; Touchon J; Bergman H; Gambina G; He Y; Rapatz G; Nagel J; Lane R
Curr Med Res Opin; 2005 Aug; 21(8):1317-27. PubMed ID: 16083542
[TBL] [Abstract][Full Text] [Related]
33. Galantamine prolonged-release formulation in the treatment of mild to moderate Alzheimer's disease.
Brodaty H; Corey-Bloom J; Potocnik FC; Truyen L; Gold M; Damaraju CR
Dement Geriatr Cogn Disord; 2005; 20(2-3):120-32. PubMed ID: 15990426
[TBL] [Abstract][Full Text] [Related]
34. Effects of memantine on cognition in patients with moderate to severe Alzheimer's disease: post-hoc analyses of ADAS-cog and SIB total and single-item scores from six randomized, double-blind, placebo-controlled studies.
Mecocci P; Bladström A; Stender K
Int J Geriatr Psychiatry; 2009 May; 24(5):532-8. PubMed ID: 19274640
[TBL] [Abstract][Full Text] [Related]
35. Potential long-term effects of rivastigmine on disease progression may be linked to drug effects on vascular changes in Alzheimer brains.
Erkinjuntti T; Skoog I; Lane R; Andrews C
Int J Clin Pract; 2003 Nov; 57(9):756-60. PubMed ID: 14686563
[TBL] [Abstract][Full Text] [Related]
36. Long-term rivastigmine treatment in a routine clinical setting.
Minthon L; Wallin AK; Eriksson S; Wattmo C; Andreasen N
Acta Neurol Scand; 2009 Mar; 119(3):180-5. PubMed ID: 18759798
[TBL] [Abstract][Full Text] [Related]
37. Donepezil preserves cognition and global function in patients with severe Alzheimer disease.
Black SE; Doody R; Li H; McRae T; Jambor KM; Xu Y; Sun Y; Perdomo CA; Richardson S
Neurology; 2007 Jul; 69(5):459-69. PubMed ID: 17664405
[TBL] [Abstract][Full Text] [Related]
38. Caregiver preference for rivastigmine patches versus capsules for the treatment of Alzheimer disease.
Blesa R; Ballard C; Orgogozo JM; Lane R; Thomas SK
Neurology; 2007 Jul; 69(4 Suppl 1):S23-8. PubMed ID: 17646620
[TBL] [Abstract][Full Text] [Related]
39. The ACTION study: methodology of a trial to evaluate safety and efficacy of a higher dose rivastigmine transdermal patch in severe Alzheimer's disease.
Farlow MR; Grossberg G; Gauthier S; Meng X; Olin JT
Curr Med Res Opin; 2010 Oct; 26(10):2441-7. PubMed ID: 20828359
[TBL] [Abstract][Full Text] [Related]
40. Differential efficacy of treatment with acetylcholinesterase inhibitors in patients with mild and moderate Alzheimer's disease over a 6-month period.
López-Pousa S; Turon-Estrada A; Garre-Olmo J; Pericot-Nierga I; Lozano-Gallego M; Vilalta-Franch M; Hernández-Ferràndiz M; Morante-Muñoz V; Isern-Vila A; Gelada-Batlle E; Majó-Llopart J
Dement Geriatr Cogn Disord; 2005; 19(4):189-95. PubMed ID: 15677866
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
